IL318052A - Treatment of aiha with baff or baff receptor inhibitory antibodies - Google Patents
Treatment of aiha with baff or baff receptor inhibitory antibodiesInfo
- Publication number
- IL318052A IL318052A IL318052A IL31805224A IL318052A IL 318052 A IL318052 A IL 318052A IL 318052 A IL318052 A IL 318052A IL 31805224 A IL31805224 A IL 31805224A IL 318052 A IL318052 A IL 318052A
- Authority
- IL
- Israel
- Prior art keywords
- baff
- aiha
- treatment
- inhibitory antibodies
- receptor inhibitory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263368825P | 2022-07-19 | 2022-07-19 | |
| US202263384051P | 2022-11-16 | 2022-11-16 | |
| PCT/IB2023/057257 WO2024018350A1 (en) | 2022-07-19 | 2023-07-17 | Treatment of aiha with baff or baff receptor inhibitory antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318052A true IL318052A (en) | 2025-02-01 |
Family
ID=87556046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318052A IL318052A (en) | 2022-07-19 | 2023-07-17 | Treatment of aiha with baff or baff receptor inhibitory antibodies |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20260139065A1 (en) |
| EP (1) | EP4558522A1 (en) |
| JP (1) | JP2025523874A (en) |
| KR (1) | KR20250040011A (en) |
| CN (1) | CN119546641A (en) |
| CA (1) | CA3261672A1 (en) |
| IL (1) | IL318052A (en) |
| TW (1) | TW202404639A (en) |
| WO (1) | WO2024018350A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026064677A2 (en) * | 2024-09-20 | 2026-03-26 | Paragon Therapeutics, Inc. | Baff receptor-binding polypeptides, compositions, and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001268427B2 (en) * | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| US11136405B2 (en) * | 2016-06-06 | 2021-10-05 | Board Of Regents, The Unviersity Of Texas System | BAFF-R antibodies and uses thereof |
| JP2022515152A (en) * | 2018-12-19 | 2022-02-17 | シティ・オブ・ホープ | BAFF-R bispecific T cell engager antibody |
-
2023
- 2023-07-17 JP JP2025501778A patent/JP2025523874A/en active Pending
- 2023-07-17 WO PCT/IB2023/057257 patent/WO2024018350A1/en not_active Ceased
- 2023-07-17 EP EP23751099.5A patent/EP4558522A1/en active Pending
- 2023-07-17 IL IL318052A patent/IL318052A/en unknown
- 2023-07-17 TW TW112126572A patent/TW202404639A/en unknown
- 2023-07-17 CN CN202380053369.6A patent/CN119546641A/en active Pending
- 2023-07-17 KR KR1020257004736A patent/KR20250040011A/en active Pending
- 2023-07-17 CA CA3261672A patent/CA3261672A1/en active Pending
- 2023-07-17 US US18/996,905 patent/US20260139065A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20260139065A1 (en) | 2026-05-21 |
| TW202404639A (en) | 2024-02-01 |
| WO2024018350A1 (en) | 2024-01-25 |
| CA3261672A1 (en) | 2024-01-25 |
| CN119546641A (en) | 2025-02-28 |
| JP2025523874A (en) | 2025-07-25 |
| KR20250040011A (en) | 2025-03-21 |
| EP4558522A1 (en) | 2025-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202010472XA (en) | Use of pilocarpine hydrochloride for the treatment of ocular conditions | |
| IL288590A (en) | Automatic prediction of blood infections | |
| LT3768304T (en) | COMPOSITIONS AND METHODS FOR ENHANCING OR ENHANCED TRANSDUCTION OF GENE THERAPY VECTORS AND REMOVING OR REDUCING IMMUNOGLOBULINS | |
| IL288523A (en) | Compounds for treatment of pd-l1 diseases | |
| IL291665A (en) | Inhibitors of receptor interacting protein kinase i for the treatment of disease | |
| MA53664A (en) | COMPOUNDS FOR THE TREATMENT OF CERTAIN LEUKEMIA | |
| IL287904B2 (en) | Combination treatment of arthritic disease | |
| IL291687A (en) | Methods for treating myelofibrosis and related conditions | |
| EP3773632A4 (en) | METHODS OF TREATMENT OF EGFRVIII-EXPRESSING GLIOBLASTOMAS | |
| MA55218A (en) | ESKETAMINE FOR THE TREATMENT OF DEPRESSION | |
| EP3504204A4 (en) | INDAZOLYL-L, 2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR THE INHIBITION OF RHO ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | |
| EP3968989A4 (en) | COMPOUND FOR THE TREATMENT OF GOUT OR HYPERURICAEMIA | |
| IL287264A (en) | Compounds and methods for the treatment of ocular disorders | |
| HUE057197T2 (en) | Process for the adjuvant treatment of naphtha | |
| EP3993787A4 (en) | ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF MUTANTS | |
| CA3261672A1 (en) | Treatment of aiha with baff or baff receptor inhibitory antibodies | |
| HUE070524T2 (en) | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab | |
| EP3985031C0 (en) | BETA GLUCAN FOR THE TREATMENT OF THROMBOCYTOPENI | |
| IL327070A (en) | Methods for the treatment of cardiovascular disease | |
| MA56179A (en) | TREATMENT OF SYNUCLEINOPATHIES | |
| PT3781210T (en) | Treatment of sepsis and septic shock | |
| EP3950707A4 (en) | Composition comprising albumin-coupled slit3 lrrd2 for prevention or treatment of muscle disease | |
| EP3934649A4 (en) | METHODS OF TREATING A DISEASE WITH LEVOKETOCONAZOLE | |
| MA53914A (en) | CRYSTALLINE POLYMORPHS OF BRUTON'S TYROSINE KINASE INHIBITORS | |
| GB201911728D0 (en) | Bacterial composistions for the treatment of disease |